Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Equillium Inc chart...

About the Company

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.

CEO

Bruce Steel

Exchange

NASDAQ

Website

http://equilliumbio.com/

$73M

Total Revenue

49

Employees

$73M

Market Capitalization

-3.61

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EQ News

Buy Rating Affirmed for Equillium Amid Promising Clinical Trials and Potential Financial Upsides

1d ago, source:

In a report released on March 25, Thomas Smith from Leerink Partners reiterated a Buy rating on Equillium (EQ – Research Report), with a ...

Equillium gets grant for inhibitors of cytokine activity using peptide antagonists

2h ago, source: Pharmaceutical Technology

Discover Equillium Inc's groundbreaking patent on peptide antagonists targeting ?c-family cytokines linked to leukemia and autoimmune disorders. This innovative patent offers therapeutic, cosmetic, ...

Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates

2d ago, source: Zacks.com on MSN

Equillium, Inc. (EQ) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.08 per share a year ago. These figures ...

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

2d ago, source: Stockhouse

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory ...

Individual investors account for 41% of Equillium, Inc.'s (NASDAQ:EQ) ownership, while insiders account for 20%

6d ago, source:

Key Insights The considerable ownership by individual investors in Equillium indicates that they collectively have ...

Equillium, Inc. (EQ) Interactive Stock Chart - Yahoo Finance

6d ago, source: Yahoo Finance

LA JOLLA, Calif., March 22, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory ...

Equillium: Q4 Earnings Insights

2d ago, source:

Equillium EQ reported its Q4 earnings results on Monday, March 25, 2024 at 04:01 PM. Here's what investors need to know about the announcement. Equillium beat estimated earnings by 59.0%, reporting an ...

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Equillium, Inc. (0FY.F)

24d ago, source: Yahoo Finance

Simply Wall St. Even after rising 85% this past week, Equillium (NASDAQ:EQ) shareholders are still down 85% over the past three years It is doubtless a positive to see that the Equillium, Inc. ( ...

Equillium, Inc. (0A4D.L)

25d ago, source: Yahoo Finance

Simply Wall St. Even after rising 85% this past week, Equillium (NASDAQ:EQ) shareholders are still down 85% over the past three years It is doubtless a positive to see that the Equillium, Inc. ( ...

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

2d ago, source: Finanznachrichten

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...